Gross Alden L, Sherva Richard, Mukherjee Shubhabrata, Newhouse Stephen, Kauwe John S K, Munsie Leanne M, Waterston Leo B, Bennett David A, Jones Richard N, Green Robert C, Crane Paul K
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md., USA.
Neuroepidemiology. 2014;43(3-4):194-205. doi: 10.1159/000367970. Epub 2014 Nov 13.
We sought to identify optimal approaches by calibrating longitudinal cognitive performance across studies with different neuropsychological batteries.
We examined four approaches to calibrate cognitive performance in nine longitudinal studies of Alzheimer's disease (AD) (n = 10,875): (1) common test, (2) standardize and average available tests, (3) confirmatory factor analysis (CFA) with continuous indicators, and (4) CFA with categorical indicators. To compare precision, we determined the minimum sample sizes needed to detect 25% cognitive decline with 80% power. To compare criterion validity, we correlated cognitive change from each approach with 6-year changes in average cortical thickness and hippocampal volume using available MRI data from the AD Neuroimaging Initiative.
CFA with categorical indicators required the smallest sample size to detect 25% cognitive decline with 80% power (n = 232) compared to common test (n = 277), standardize-and-average (n = 291), and CFA with continuous indicators (n = 315) approaches. Associations with changes in biomarkers changes were the strongest for CFA with categorical indicators.
CFA with categorical indicators demonstrated greater power to detect change and superior criterion validity compared to other approaches. It has wide applicability to directly compare cognitive performance across studies, making it a good way to obtain operational phenotypes for genetic analyses of cognitive decline among people with AD.
我们试图通过校准使用不同神经心理测试组合的研究中的纵向认知表现来确定最佳方法。
我们在9项阿尔茨海默病(AD)纵向研究(n = 10,875)中检验了4种校准认知表现的方法:(1)共同测试,(2)对可用测试进行标准化和平均,(3)使用连续指标的验证性因子分析(CFA),以及(4)使用分类指标的CFA。为了比较精度,我们确定了以80%的检验效能检测25%认知衰退所需的最小样本量。为了比较效标效度,我们使用来自阿尔茨海默病神经影像倡议组织的可用MRI数据,将每种方法的认知变化与平均皮质厚度和海马体积的6年变化进行关联。
与共同测试(n = 277)、标准化和平均(n = 291)以及使用连续指标的CFA(n = 315)方法相比,使用分类指标的CFA以80%的检验效能检测25%认知衰退所需的样本量最小(n = 232)。使用分类指标的CFA与生物标志物变化的关联最强。
与其他方法相比,使用分类指标的CFA在检测变化方面表现出更强的效能和更高的效标效度。它在直接比较不同研究中的认知表现方面具有广泛的适用性,使其成为获得AD患者认知衰退遗传分析操作表型的良好方法。